Locci Cristian, Cenere Caterina, Sotgiu Giovanni, Puci Mariangela Valentina, Saderi Laura, Rizzo Davide, Bussu Francesco, Antonucci Roberto
Pediatric Clinic, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
J Clin Med. 2023 Sep 7;12(18):5826. doi: 10.3390/jcm12185826.
Adenotonsillectomy (AT) is the first-line treatment for pediatric obstructive sleep apnea syndrome (OSAS). Relatively few studies have evaluated the clinical and functional outcomes of AT in children with OSAS, but these studies show that surgery improves behavior and quality of life (QOL). However, residual OSAS after AT is reported in severe cases. This study aimed to retrospectively evaluate the clinical and functional outcomes of AT in a cohort of children with OSAS. We consecutively enrolled children with OSAS who underwent AT and were admitted to our clinic from 1 July 2020 to 31 December 2022. For each participant, medical history and physical examinations were performed. Before and after surgery, all patients underwent a standard polygraphic evaluation, and caregivers completed the OSA-18 questionnaire. A total of 65 children with OSAS, aged 2-9 years, were included. After AT, 64 (98.4%) children showed a reduction in AHI, with median (IQR) values decreasing from 13.4/h (8.3-18.5/h) to 2.4/h (1.8-3.1/h) (-value < 0.0001). Conversely, median (IQR) SpO nadir increased after surgery from 89% (84-92%) to 94% (93-95%) (-value < 0.0001). Moreover, 27 children (18%) showed residual OSAS. The OSA-18 score decreased after AT from median (IQR) values of 84 (76-91) to values of 33 (26-44) (-value < 0.0001). A positive significant correlation was found between OSA-18 post-operative scores and AHI post-operative scores (rho 0.31; -value = 0.01). Our findings indicate that, in children with OSAS, AT is associated with significant improvements in behavior, QOL, and polygraphic parameters. However, long-term post-surgical follow-up to monitor for residual OSAS is highly recommended, especially in more severe cases.
腺样体扁桃体切除术(AT)是小儿阻塞性睡眠呼吸暂停综合征(OSAS)的一线治疗方法。相对较少的研究评估了AT治疗OSAS患儿的临床和功能结局,但这些研究表明手术可改善行为和生活质量(QOL)。然而,严重病例中报道了AT术后残留OSAS的情况。本研究旨在回顾性评估一组OSAS患儿接受AT后的临床和功能结局。我们连续纳入了2020年7月1日至2022年12月31日期间在我们诊所接受AT并入院的OSAS患儿。对每位参与者进行了病史采集和体格检查。手术前后,所有患者均接受了标准的多导睡眠监测评估,且照料者完成了OSA-18问卷。共纳入65例年龄在2至9岁的OSAS患儿。AT术后,64例(98.4%)患儿的呼吸暂停低通气指数(AHI)降低,中位数(四分位间距)值从13.4次/小时(8.3 - 18.5次/小时)降至2.4次/小时(1.8 - 3.1次/小时)(P值<0.0001)。相反,术后最低血氧饱和度(SpO)中位数(四分位间距)从89%(84 - 92%)升至94%(93 - 95%)(P值<0.0001)。此外,27例患儿(18%)存在残留OSAS。AT术后OSA-18评分中位数(四分位间距)从84(76 - 91)降至33(26 - 44)(P值<0.0001)。术后OSA-18评分与术后AHI评分之间存在显著正相关(相关系数ρ为0.31;P值 = 0.01)。我们的研究结果表明,对于OSAS患儿,AT与行为、生活质量和多导睡眠监测参数的显著改善相关。然而,强烈建议进行长期术后随访以监测残留OSAS情况,尤其是在更严重的病例中。